Which has higher earnings and valuation, PGNY or HIMS?

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.59 $58.52M $0.77 33.87 Hims & Hers Health $2.35B 3.49 $128.37M -$0.09 N/A

Does the media refer more to PGNY or HIMS?

In the previous week, Hims & Hers Health had 20 more articles in the media than Progyny. MarketBeat recorded 23 mentions for Hims & Hers Health and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Hims & Hers Health's score of 0.76 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 11 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PGNY or PACS?

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.59 $58.52M $0.77 33.87 PACS Group $5.29B 1.10 $191.54M $1.56 23.51

Is PGNY or PACS more profitable?

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Progyny 5.23% 13.34% 9.03% PACS Group 4.49% 26.47% 4.36%

Does the media refer more to PGNY or PACS?

In the previous week, PACS Group had 5 more articles in the media than Progyny. MarketBeat recorded 8 mentions for PACS Group and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat PACS Group's score of -0.12 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CAI or PGNY?

In the previous week, Caris Life Sciences had 2 more articles in the media than Progyny. MarketBeat recorded 5 mentions for Caris Life Sciences and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Caris Life Sciences' score of 0.31 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Progyny 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, PGNY or BLLN?

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Progyny $1.29B 1.59 $58.52M $0.77 33.87 Billiontoone $305.11M 15.85 $7.45M $0.55 191.18

Does the media favor PGNY or BLLN?

In the previous week, Billiontoone had 2 more articles in the media than Progyny. MarketBeat recorded 5 mentions for Billiontoone and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Billiontoone's score of -0.44 indicating that Progyny is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Progyny 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SHC or PGNY more profitable?

Sotera Health has a net margin of 9.91% compared to Progyny's net margin of 5.23%. Sotera Health's return on equity of 39.73% beat Progyny's return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% Progyny 5.23% 13.34% 9.03%

Does the media refer more to SHC or PGNY?

In the previous week, Progyny had 2 more articles in the media than Sotera Health. MarketBeat recorded 3 mentions for Progyny and 1 mentions for Sotera Health. Progyny's average media sentiment score of 1.24 beat Sotera Health's score of 0.00 indicating that Progyny is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Progyny 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Progyny (PGNY) Competitors

$26.08 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$25.29 -0.79 (-3.04%)

As of 06/18/2026 07:57 PM Eastern

Compare

PGNY vs. HIMS, PACS, CAI, BLLN, and SHC

Should you buy Progyny stock or one of its competitors? MarketBeat compares Progyny with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Progyny include Hims & Hers Health (HIMS), PACS Group (PACS), Caris Life Sciences (CAI), Billiontoone (BLLN), and Sotera Health (SHC). These companies are all part of the "healthcare" industry.

How does Progyny compare to Hims & Hers Health?

Progyny (NASDAQ:PGNY) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Progyny currently has a consensus price target of $29.67, indicating a potential upside of 13.75%. Hims & Hers Health has a consensus price target of $29.37, indicating a potential downside of 17.14%. Given Progyny's stronger consensus rating and higher possible upside, analysts clearly believe Progyny is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Hims & Hers Health	3 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.06

In the previous week, Hims & Hers Health had 20 more articles in the media than Progyny. MarketBeat recorded 23 mentions for Hims & Hers Health and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Hims & Hers Health's score of 0.76 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hims & Hers Health	11 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Progyny has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.37, meaning that its stock price is 137% more volatile than the broader market.

94.9% of Progyny shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Progyny has a net margin of 5.23% compared to Hims & Hers Health's net margin of -0.56%. Progyny's return on equity of 13.34% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Hims & Hers Health	-0.56%	6.10%	1.52%

Hims & Hers Health has higher revenue and earnings than Progyny. Hims & Hers Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.59	$58.52M	$0.77	33.87
Hims & Hers Health	$2.35B	3.49	$128.37M	-$0.09	N/A

Summary

Progyny beats Hims & Hers Health on 10 of the 16 factors compared between the two stocks.

How does Progyny compare to PACS Group?

Progyny (NASDAQ:PGNY) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

PACS Group has higher revenue and earnings than Progyny. PACS Group is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.59	$58.52M	$0.77	33.87
PACS Group	$5.29B	1.10	$191.54M	$1.56	23.51

Progyny has a net margin of 5.23% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
PACS Group	4.49%	26.47%	4.36%

94.9% of Progyny shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Comparatively, 70.1% of PACS Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, PACS Group had 5 more articles in the media than Progyny. MarketBeat recorded 8 mentions for PACS Group and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat PACS Group's score of -0.12 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Progyny currently has a consensus price target of $29.67, indicating a potential upside of 13.75%. PACS Group has a consensus price target of $48.00, indicating a potential upside of 30.88%. Given PACS Group's higher possible upside, analysts clearly believe PACS Group is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Progyny beats PACS Group on 8 of the 15 factors compared between the two stocks.

How does Progyny compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Progyny (NASDAQ:PGNY) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

Caris Life Sciences currently has a consensus target price of $27.56, suggesting a potential upside of 49.19%. Progyny has a consensus target price of $29.67, suggesting a potential upside of 13.75%. Given Caris Life Sciences' higher possible upside, analysts plainly believe Caris Life Sciences is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Progyny	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79

Progyny has a net margin of 5.23% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Progyny	5.23%	13.34%	9.03%

Progyny has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	6.43	-$68.09M	-$7.61	N/A
Progyny	$1.29B	1.59	$58.52M	$0.77	33.87

94.9% of Progyny shares are held by institutional investors. 50.0% of Caris Life Sciences shares are held by company insiders. Comparatively, 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Caris Life Sciences had 2 more articles in the media than Progyny. MarketBeat recorded 5 mentions for Caris Life Sciences and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Caris Life Sciences' score of 0.31 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Progyny beats Caris Life Sciences on 9 of the 15 factors compared between the two stocks.

How does Progyny compare to Billiontoone?

Progyny (NASDAQ:PGNY) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

Progyny has higher revenue and earnings than Billiontoone. Progyny is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.29B	1.59	$58.52M	$0.77	33.87
Billiontoone	$305.11M	15.85	$7.45M	$0.55	191.18

94.9% of Progyny shares are owned by institutional investors. 9.9% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Progyny currently has a consensus price target of $29.67, indicating a potential upside of 13.75%. Billiontoone has a consensus price target of $125.29, indicating a potential upside of 19.15%. Given Billiontoone's higher probable upside, analysts plainly believe Billiontoone is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Progyny has a net margin of 5.23% compared to Billiontoone's net margin of 0.00%. Progyny's return on equity of 13.34% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Progyny	5.23%	13.34%	9.03%
Billiontoone	N/A	N/A	N/A

In the previous week, Billiontoone had 2 more articles in the media than Progyny. MarketBeat recorded 5 mentions for Billiontoone and 3 mentions for Progyny. Progyny's average media sentiment score of 1.24 beat Billiontoone's score of -0.44 indicating that Progyny is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Progyny beats Billiontoone on 11 of the 15 factors compared between the two stocks.

How does Progyny compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

In the previous week, Progyny had 2 more articles in the media than Sotera Health. MarketBeat recorded 3 mentions for Progyny and 1 mentions for Sotera Health. Progyny's average media sentiment score of 1.24 beat Sotera Health's score of 0.00 indicating that Progyny is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Progyny	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sotera Health presently has a consensus target price of $20.29, indicating a potential upside of 28.23%. Progyny has a consensus target price of $29.67, indicating a potential upside of 13.75%. Given Sotera Health's higher possible upside, equities research analysts plainly believe Sotera Health is more favorable than Progyny.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Progyny	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79

Sotera Health has higher earnings, but lower revenue than Progyny. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	3.88	$77.94M	$0.41	38.59
Progyny	$1.29B	1.59	$58.52M	$0.77	33.87

91.0% of Sotera Health shares are owned by institutional investors. Comparatively, 94.9% of Progyny shares are owned by institutional investors. 15.4% of Sotera Health shares are owned by company insiders. Comparatively, 9.9% of Progyny shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Sotera Health has a net margin of 9.91% compared to Progyny's net margin of 5.23%. Sotera Health's return on equity of 39.73% beat Progyny's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
Progyny	5.23%	13.34%	9.03%

Sotera Health has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Progyny has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Summary

Sotera Health and Progyny tied by winning 8 of the 16 factors compared between the two stocks.

Get Progyny News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PGNY vs. The Competition

Export

Metric	Progyny	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.04B	$8.76B	$6.42B	$12.59B
Dividend Yield	N/A	1.73%	2.68%	5.81%
P/E Ratio	33.87	24.73	24.78	24.44
Price / Sales	1.59	22.64	533.42	111.25
Price / Cash	35.43	102.97	45.07	55.09
Price / Book	4.35	5.64	10.80	6.58
Net Income	$58.52M	$179.69M	$3.57B	$337.17M
7 Day Performance	-2.07%	1.96%	0.72%	0.83%
1 Month Performance	5.63%	2.99%	0.41%	2.25%
1 Year Performance	24.31%	6.36%	29.34%	36.14%

Progyny Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PGNY Progyny	4.0238 of 5 stars	$26.08 flat	$29.67 +13.8%	+24.3%	$2.04B	$1.29B	33.87	310	Positive News Gap Up High Trading Volume
HIMS Hims & Hers Health	3.0216 of 5 stars	$30.10 +12.2%	$28.70 -4.6%	-45.0%	$6.21B	$2.35B	N/A	2,442	Analyst Forecast Insider Trade Gap Down
PACS PACS Group	3.7915 of 5 stars	$36.23 -0.2%	$48.00 +32.5%	+176.8%	$5.74B	$5.29B	23.22	47,455	News Coverage Insider Trade Gap Up
CAI Caris Life Sciences	4.3745 of 5 stars	$18.18 +1.2%	$27.56 +51.6%	N/A	$5.08B	$812.03M	N/A	1,846
BLLN Billiontoone	3.2865 of 5 stars	$103.95 +2.8%	$125.29 +20.5%	N/A	$4.65B	$305.11M	189.00	620	News Coverage Insider Trade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PGNY) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Progyny (PGNY) Competitors

PGNY vs. HIMS, PACS, CAI, BLLN, and SHC

How does Progyny compare to Hims & Hers Health?

Summary

How does Progyny compare to PACS Group?

Summary

How does Progyny compare to Caris Life Sciences?

Summary

How does Progyny compare to Billiontoone?

Summary

How does Progyny compare to Sotera Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Progyny (PGNY) Competitors

PGNY vs. HIMS, PACS, CAI, BLLN, and SHC

How does Progyny compare to Hims & Hers Health?

Do analysts prefer PGNY or HIMS?

Does the media refer more to PGNY or HIMS?

Which has more risk & volatility, PGNY or HIMS?

Do institutionals & insiders believe in PGNY or HIMS?

Is PGNY or HIMS more profitable?

Which has higher earnings and valuation, PGNY or HIMS?

Summary

How does Progyny compare to PACS Group?

Which has higher earnings and valuation, PGNY or PACS?

Is PGNY or PACS more profitable?

Do institutionals & insiders believe in PGNY or PACS?

Does the media refer more to PGNY or PACS?

Do analysts prefer PGNY or PACS?

Summary

How does Progyny compare to Caris Life Sciences?

Do analysts recommend CAI or PGNY?

Is CAI or PGNY more profitable?

Which has stronger earnings & valuation, CAI or PGNY?

Do institutionals and insiders hold more shares of CAI or PGNY?

Does the media refer more to CAI or PGNY?

Summary

How does Progyny compare to Billiontoone?

Which has stronger earnings & valuation, PGNY or BLLN?

Do institutionals and insiders have more ownership in PGNY or BLLN?

Do analysts recommend PGNY or BLLN?

Is PGNY or BLLN more profitable?

Does the media favor PGNY or BLLN?

Summary

How does Progyny compare to Sotera Health?

Does the media refer more to SHC or PGNY?

Do analysts recommend SHC or PGNY?

Which has stronger valuation & earnings, SHC or PGNY?

Do institutionals & insiders believe in SHC or PGNY?

Is SHC or PGNY more profitable?

Which has more risk and volatility, SHC or PGNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGNY vs. The Competition

Progyny Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools